Showing Latest Articles
Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome
American Journal of Obstetrics and Gynecology, 08/25/2011
Sand PK et al. – Oxybutynin chloride topical gel (OTG) was well tolerated and provided significant improvement in urinary symptoms and health–related quality–of–life (HRQoL) in women with overactive bladder syndrome (OAB).
Methods- Women (N = 704) with urgency-predominant urinary incontinence received OTG or placebo for 12 weeks.
- The primary end point was change from baseline to last observation in number of daily incontinence episodes.
- Treatments were compared using ANCOVA.
- OTG significantly reduced the number (mean [standard deviation]) of daily incontinence episodes (OTG, -3.0 [2.8]; placebo, -2.5 [3.0]; P < .0001), reduced urinary frequency ( P = .0013), increased voided volume (P = .0006), and improved select health-related quality-of-life (HRQoL) domains (P <=.0161) vs placebo.
- Dry mouth was the only drug-related adverse event significantly more common with OTG (7.4%) than placebo (2.8%) (P = .0062).
